🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our paper on the efficacy and safety of trifluridine/tipiracil combined with bevacizumab for refractory colorectal cancer patients is now available at ecancer. Discover how different patient subgroups respond to this treatment: doi.org/10.3332/ecance…

How to develop an academic argument: ⬇️ A strong academic argument clearly presents your position, supports it with evidence, and persuade your audience of its validity.

🔍 Avaiable in the World Journal of Surgical oncology: explore the findings of our comprehensive review and meta-analysis on the radicality and safety of total mesopancreatic excision in pancreatoduodenectomy. Read the full paper: wjso.biomedcentral.com/articles/10.11…

“Acredito que a premiação representa o protagonismo brasileiro em iniciativas de pesquisa independentes e nossa capacidade de produzir trabalhos de impacto”, observa Luís Felipe Leite da Silva. Leia mais: shorturl.at/hPmvS ASCO Jp Solar Vasconcelos #GI25

pubmed.ncbi.nlm.nih.gov/39998904/ Our meta-analysis aggregates data from more the 30 studies comprising 3000+ patients, showing that ctDNA decrease and clearance are strongly associated with PFS and OS in lung cancer. Results hold true for targeted treatments and immunotherapy! @iaslc

International Society of Liquid Biopsy

This is a nice effort from a Brazilian 🇧🇷 large team led by our good friend gilberto lopes Sylvester Comprehensive Cancer Center —the application can one day happen beyond lung cancer and perhaps decrease the intensity of CTs The Oncologist IASLC

Happy to share our work led by the rising star Luís Felipe Leite, highlighting the role of ctDNA kinetics in predicting treatment outcomes for patients with NSCLC. Check it out! 💥 International Society of Liquid Biopsy Carolina Reduzzi

ctDNA decrease and clearance are associated with PFS and OS in lung cancer - gilberto lopes oncodaily.com/science/ctdna-… #LungCancer #LCSM #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

🚨 Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC 🧬🩸 📊 Key Findings from a Systematic Review & Meta-Analysis: ✅ ctDNA clearance/decrease strongly correlates with improved PFS & OS in NSCLC patients. ✅ HR for PFS: 0.32 ( 68% lower risk of progression

Impacto cinética ctDNA e tratamento mCPNPC: metanálise - Depuração ctDNA: >> ⬆️ SLP (HR 0,32 CI 0,26-0,40). Melhor em pcts submetidos à terapia-alvo 🎯 e IO >> ⬆️ SG (HR 0,31 CI 0,23-0,42) >> sem diferença por subtipo CPNPC, tabagismo, sexo. acrobat.adobe.com/id/urn:aaid:sc…

Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC - International Society of Liquid Biopsy oncodaily.com/science/nsclc #NSCLC #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

Thank you The ASCO Post for featuring our The Oncologist paper on the role of ctDNA dynamics in non-small cell lung #cancer. ascopost.com/news/march-202… We look forward to the next steps in liquid biopsy and precision oncology in thoracic #Oncology.

Absence of ctDNA clearance may identify patients unlikely to achieve pCR after neoadjuvant ICIs. However, limited specificity means current evidence does not support its use to guide treatment de-escalation. Impressive analysis by Dr. Saldanha in Annals of Oncology. OncoDaily

Luís Felipe Leite Annals of Oncology We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/insight/erick-…

Learning from Dr.Bishal Gyawali, MD, PhD, FASCO has been an honor! Read our manuscript avaliable in BMJ Oncology We hope these findings encourage thoughtful consideration of endpoints in future trial designs, balancing shorter-term gains with long-term outcomes for patients.

Our new manuscript is now available in open access👇🏻 Check it out below and let us know your thoughts! Erick Saldanha, MD The ASCO Post BMJ Oncology

Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis Read this new #OriginalResearch from Bishal Gyawali, MD, PhD, FASCO , Luís Felipe Leite , and colleagues in BMJ Oncology now OncoAlert #OncoAlert

Let’s raise awareness about early-onset cancer. 📊 New study in JCO Global Oncology shows early-onset pancreatic cancer (EOPC) is rising worldwide — especially in low- & middle-income countries. 🔗 doi.org/10.1200/GO-25-… The ASCO Post

Wrapping up some memories from the Brazilian Breast Cancer Symposium 2025. It was an amazing event where I had the chance to make new friends and present our research project (the REIGNITE Study) — which even received an award!